




Medicure Inc. Investor Presentation 2025



Forward Looking Statement



This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for Medicure Inc., business and operational results. By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, product recalls, competition from similar products and other factors including those risks and uncertainties identified above, and those contained in the Company's most recent MD&A and Form 20F.

Medicure Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

Medicure's 5 Focuses



Medicure is an R&D specialty pharmaceutical and pharmacy company focused on the US market

1. Growing sales of **ZYPITAMAG**®
2. Growing sales of **Marley Drug**® E-Commerce pharmacy subsidiary
3. Maintain sales of **AGGRASTAT**®
4. Complete **Phase 3 Trial** of MC-1 for 10 PNPO patients to receive priority review voucher
5. Begin pre-clinical development of **New Chemical Entity** analogues of pyridoxal 5'-phosphate

Medicure has No Debt

Medicure's Growth Strategy



Medicure plans to use its profit to fund R&D and acquisitions

Short term:

Growth of ZYPITAMAG,
Marley Drug and maintain
AGGRASTAT

Near term:

Build the Marley Drug
business through acquisition
and partnerships

Use revenue from sale of
MC-1 voucher upon approval
to accelerate growth

Long term:



Development of acquired
new chemical entities for
large unmet needs

Medicure's Pharmacy Acquisitions – Why?



- A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug
- A profitable marketing vehicle for other branded drugs
- Saves on high fees to wholesalers and pharmacy benefit managers
- Medicure recently acquired Gateway Medical Pharmacy to build our customer base and for brand expansion



Key Financial Parameters



Key Financial Parameters



Key Financial Parameters



Net Income before Non-Cash Adjustments



Net Income (Loss) after Non-Cash Adjustments



Medicure's Leadership Team



Albert D. Friesen
Chief Executive Officer &
Chairman of the Board

- Founded Medicure in 1997
- Created and developed multiple companies, including ABI Biotechnology (Apotex Fermentation), The Winnipeg Rh Institute, DiaMedica and Genesys Venture Inc.



Neil Owens
President &
Chief Operating Officer

- President & COO since 2019
- Joined Medicure in 2014 in Medical Affairs
- PhD in Organic Chemistry
- Responsible for the execution of strategic plans and oversight of operations



Haaris Uddin
Chief Financial Officer

- Joined Medicure in 2022 as CFO
- Responsible for financial reporting activities and oversight of finance systems and strategy



Reuben Saba
Vice President,
Business Development

- VP since 2019
- Joined Medicure in 2014 in Medical Affairs
- PhD in Neurobiology
- Responsible for the development of new business opportunities

Zypitamag[®]

(pitavastatin) tablets

\$6.2M

In 2024

↑24%

from the prior year

\$4B

Statin market

INDICATION

High Cholesterol

PRODUCT HIGHLIGHTS

- Improvements over older statins
- Low rates of side effects like muscle pain
- Doesn't interact with other medications
- Once daily low dose with strong LDL reduction

LEARN MORE AT
Zypitamag.com



medicure[®]



Medicare's Pharmacy Subsidiary & E-Commerce Website

\$10.8M

In 2024

↑12.5%

from the prior year

\$40B

Online pharmacy
market

WHAT IS MARLEY DRUG

- A US pharmacy subsidiary licensed to ship FDA approved medications to all 50 states
- Facilitates Medicare selling ZYPITAMAG directly to consumers

HIGHLIGHTS

- Increased ZYPITAMAG units dispensed by 17% compared to prior year
- Also sells most generic and branded medications
- E-commerce website for easy ordering and refills

LEARN MORE AT
MarleyDrug.com



AGGR[^]STAT[®]

(tirofiban hydrochloride) Injection

\$8.1M

In 2024

INDICATION

Acute Coronary Syndrome

PRODUCT HIGHLIGHTS

- Leading IV antiplatelet in its class
- Medicure grew market share from 2% to 65%
- Used in more than 1,000 hospitals
- Three formats of the product available

LEARN MORE AT
Aggrastat.com



PHASE 3 CLINICAL STUDY

Development of MC-1 for Rare Pediatric Disease

Phase 3 study for treatment of rare pediatric disease called PNPO deficiency

- Study involves 10-15 patients in US and Australia
- Orphan Drug Status and Fast Track Designation
- Study is ongoing
- If approved Medicure is eligible for a priority review voucher (PRV), which can be redeemed or sold
- **Previous PRV's have been sold for over \$75 million** (based on market demand)
- Medicure has significant experience with MC-1 through exploration of other clinical applications



R&D PIPELINE

Development of New Chemical Entities

Medicure acquired intellectual property related to analogues of pyridoxal 5'-phosphate

- Significant advantages over existing compounds
- Clinical targets have not yet been disclosed
- Targeting large unmet therapeutic needs
- Currently in pre-clinical development



Thank You for Your Interest

For Further Information

Visit our Websites

Medicure.com

AGGRASTAT.com

ZYPITAMAG.com

Marley Drug.com

Investor Relations

ir@medicure.com

1-888-435-2220 (Ext. 228)

Follow us on [LinkedIn](#)